XML 18 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity (Details Textual) (USD $)
 0 Months Ended 3 Months Ended 3 Months Ended
May 12, 2014
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2014
IPO [Member]
Mar. 31, 2014
IPO [Member]
Jun. 30, 2014
Restricted Stock Units (RSUs) [Member]
Jun. 30, 2013
Restricted Stock Units (RSUs) [Member]
May 11, 2014
Restricted Stock Units (RSUs) [Member]
Jun. 30, 2014
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period   0             154,290
Share Price                 $ 6.6608
Stock Issued During Period, Value, Stock Options Exercised   $ 1,028,000              
Share based Compensation Arrangement By Share based Payment Award Forfeiture Rights   0.00%              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value   $ 4.79              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value   1,593,000              
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period           409,355      
Allocated Share-based Compensation Expense   66,000 0     89,000 0    
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized   1,527,000       2,059,000      
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition   2 years 10 months 24 days       2 years 10 months 24 days      
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options   $ 431,000           $ 431,000  
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights   RSUs for 341,000 shares of common stock vest ratably over three years on a quarterly basis and had an aggregate grant date value of $2,148,000. RSUs for 68,355 shares had an aggregate grant date value of $431,000 and vest in equal installments based on achievement of the following: (1) enrollment of the first patient in the first pivotal clinical trial for RUT58-60 on or prior to May 11, 2017; (2) enrollment of the first patient in the second pivotal clinical trial for RUT58-60 on or prior to May 11, 2018; and (3) completion of the clinical study report containing the results of the second pivotal clinical trial for RUT58-60 on or prior to May 11, 2019.              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 332,500 332,500              
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price $ 6.37 $ 6.37              
Warrants to Purchase of Common Stock       5,400          
Initial Public Offering Price Per Unit         $ 7.25        
Class of Warrant or Right, Exercise Price of Warrants or Rights       $ 9.0625          
Initial Public Offering Units         2,650,000